cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Alkermes Plc
3 own
14 watching
Current Price
$0
$0.1
(0.35%)
logo-alks
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
4,730.29M
52-Week High
52-Week High
32.79
52-Week Low
52-Week Low
21.75
Average Volume
Average Volume
0.18M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization4,730.29M
icon52-Week High32.79
icon52-Week Low21.75
iconAverage Volume0.18M
iconDividend Yield--
iconP/E Ratio--
What does the Alkermes Plc do?
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company's marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Read More
How much money does Alkermes Plc make?
News & Events about Alkermes Plc.
Zolmax
2 months ago
Alkermes plc (NASDAQ:ALKS Get Rating) Research analysts at SVB Leerink lowered their FY2024 earnings estimates for Alkermes in a report released on Wednesday, November 2nd. SVB Leerink analyst M. Goodman now forecasts that the company will earn $0.45 per share for the year, down from their prior ...
Ticker Report
6 months ago
Alkermes (NASDAQ:ALKS Get Rating) had its price target decreased by stock analysts at Mizuho from $36.00 to $34.00 in a research report issued on Thursday, MarketBeat.com reports. The brokerage presently has a buy rating on the stock. Mizuhos price objective points to a ...
Business Wire
8 months ago
Sarissa Capital Management LP (Sarissa) today made the following statement regarding Alkermes plc (NASDAQ: ALKS): Sarissa is disappointed that our discussions with Richard Pops, CEO of Alkermes, regarding the nominations of directors was abruptly ended by the companys sudden announcement of its...
PR Newswire
8 months ago
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028 Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028 PR Newswire PALM BEACH, Fla., May 26, 2022 FinancialNewsMedia.com News Commentary PALM BEACH, Fla., May 26, 2022...
PR Newswire
10 months ago
Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions PR Newswire PALM BEACH, Fla., March 8, 2022 PALM BEACH, Fla...
Frequently Asked Questions
Frequently Asked Questions
What is Alkermes Plc share price today?
plus_minus_icon
Can Indians buy Alkermes Plc shares?
plus_minus_icon
How can I buy Alkermes Plc shares from India?
plus_minus_icon
Can Fractional shares of Alkermes Plc be purchased?
plus_minus_icon
What are the documents required to start investing in Alkermes Plc stocks?
plus_minus_icon
What is today’s traded volume of Alkermes Plc?
plus_minus_icon
What is today’s market capitalisation of Alkermes Plc?
plus_minus_icon
What is the 52-Week High and Low Range of Alkermes Plc?
plus_minus_icon
What percentage is Alkermes Plc down from its 52-Week High?
plus_minus_icon
What percentage is Alkermes Plc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.1
(0.35%)
logo-alks
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$39.90
$0.66 (1.68 %)
Catalent, Inc.
Catalent, Inc.
$52.59
$0.00 (0.00 %)
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
$44.60
$1.62 (3.77 %)
Prestige Brands Holdings Inc
Prestige Brands Holdings Inc
$66.06
$0.00 (0.00 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
$39.90
$0.66 (1.68 %)
Catalent, Inc.
Catalent, Inc.
$52.59
$0.00 (0.00 %)
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
$44.60
$1.62 (3.77 %)
Prestige Brands Holdings Inc
Prestige Brands Holdings Inc
$66.06
$0.00 (0.00 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00